Brainstorm Cell Therapeutics Inc. · OTC:BCLI

Brainstorm Cell Therapeutics — Investor Presentation (February 2019)

22 slides from Brainstorm Cell Therapeutics's investor presentation, February 2019

  1. Slide 1: BrainStorm Cell Therapeutics

    ‫בס"ד‬ BrainStorm Cell Therapeutics Prepared NASDAQ: BCLI Chaim Lebovits, CEO February 2019 March 22, 2018

  2. Slide 2: Forward Looking Statement

    ‫בס"ד‬ Forward Looking Statement Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implie

  3. Slide 3: Brainstorm at a Glance

    ‫בס"ד‬ Brainstorm at a Glance Targeted, innovative, proprietary and validated autologous cellular technology platform for the treatment of neurodegenerative disease Actively recruiting ALS phase 3 Clinical Trial, an orphan disease with no cure and limited treatment options Large addressable market –

  4. Slide 4: NurOwn Technology

    ‫בס"ד‬ NurOwn® Technology 1 2 Isolation Expansion Manufacturing process begins with a Patient-derived MSCs secrete bone marrow aspiration to harvest neurotrophic factors and anti- adult MSCs from the patient inflammatory cytokines Harvesting Cryopreservation Transplantation The cells are injected in

  5. Slide 5: NurOwn - Potential Clinical Indications

    ‫בס"ד‬ NurOwn® - Potential Clinical Indications Parkinson’s Disease Global patients 10,000,000 US patients 1,000,000 ALS Huntington’s Global patients 450,000 Disease US patients 30,000 Global patients 300,000 Progressive US patients 30,000 Multiple Sclerosis Global patients 2,300,000 US patients 500

  6. Slide 6: ALS Facts and Figures

    ‫בס"ד‬ ALS Facts and Figures Someone is diagnosed New cases per year ALS Global Prevalence with ALS every 90minutes 6,000 450,000 Worldwide, ALS affects males ALS US Prevalence Men aged are more likely to be diagnosed with ALS than women 50+ more than any other group 30,000

  7. Slide 7: NurOwn ALS Development

    ‫בס"ד‬ NurOwn® ALS Development H1/2020 US Phase 3 Topline Data 2017 Readout ALS US Phase 3 2014 ALS 2010 US Phase 2 2007 ALS Phase 1/2a NurOwn Early Development 200 # of Study Participants 48 26 Phase 1/2 Phase 2 Phase 3 7

  8. Slide 8: ALS Phase 2 Trial Design and Safety Outcomes

    ‫בס"ד‬ ALS Phase 2 Trial Design and Safety Outcomes Safety Design Study Timeline • 48 participants (16 per site) -12 to -16 weeks Screening (V1) • Randomized 3:1 • Blinded to allocation ~3-4 months Primary Outcomes -3 to -5 weeks BMA (V4) • No deaths or treatment Transplantation related SAEs CSF Wee

  9. Slide 9: Phase 2 Trial – Approach to Data Analysis

    ‫בס"ד‬ Phase 2 Trial – Approach to Data Analysis ✓ ALS functional decline in rapid progressors more Pre-specified Efficacy Analyses closely predicts survival and quality of life 3. Rapid vs. slow ✓ Higher response rate in 1. Mean change in 2. Responder Analysis progressor subgroups slope prespecifie

  10. Slide 10: Phase 2 ALSFRS-R slope improvement: mean slope change/month

    ‫בס"ד‬ Phase 2 ALSFRS-R slope improvement: mean slope change/month All participants (n=46) Rapid progressors (n=21) Post-treatment - pre treatment slope Post treatment – pre treatment slope ALSFRS-R LS mean change in slope ALSFRS-R LS mean change in slope 2 4 1 2 0 0 (1) (2) (1) (2) 2wks 4wks 8wks 1

  11. Slide 11: Phase 2 ALSFRS-R Responder Analysis

    ‫בס"ד‬ Phase 2 ALSFRS-R Responder Analysis: ≥1.5 points/month slope improvement All participants (n=46) Rapid progressors (n=21) ALSFRS-R ≥ 1.5 points improvement/month in ALSFRS-R ≥ 1.5 points improvement in post-treatment slope post-treatment slope compared to pre-treatment slope compared to pre-t

  12. Slide 12: Phase 2 CSF NTFs Significantly Increased 2 Weeks Post-Treatment

    ‫בס"ד‬ Phase 2 CSF NTFs Significantly Increased 2 Weeks Post-Treatment Compared to Baseline VEGF (1) HGF (1) LIF (1) Pg/ml Pg/ml Pg/ml 1,000 * 600 ** 18 *** NurOwn® 800 480 15 12 600 360 (n = 26) 9 400 240 6 200 120 3 0 0 0 V5 V6 V5 V6 V5 V6 Pre transplantation Post transplantation VEGF (1) HGF (1)

  13. Slide 13: Phase 2 CSF Inflammatory Markers Significantly Decreased

    ‫בס"ד‬ Phase 2 CSF Inflammatory Markers Significantly Decreased 2 weeks Post-Treatment Compared to Baseline CRP MCP-1 SDF-1 MIP-1b Pg/ml Pg/ml Pg/ml Pg/ml 1,600 50 *** 250 ** 10 NurOwn® 1,280 40 200 8 960 30 150 6 (n = 26) 640 20 100 4 320 10 50 2 0 0 0 0 V5 V6 V5 V6 V5 V6 V5 V6 Pre transplantation

  14. Slide 14: NurOwn ALS Phase 3 Clinical Trial

    ‫בס"ד‬ NurOwn® ALS Phase 3 Clinical Trial Pre-Treatment Treatment Outcomes • Inclusion criteria • N=200 patients • ALSFRS-R responder analysis ▪ Less than 60 years of age ▪ Enrollment completed by (post-treatment slope change) ▪ SVC > 65% mid-2019 • Safety ▪ ALS ≤ 2 years • 1:1 randomization • ALSFR

  15. Slide 15: MS Facts and Figures

    ‫בס"ד‬ MS Facts and Figures* US MS prevalence Progressive MS 1M 50% Women $4.3B are more likely to be diagnosed with MS than men US annual economic burden Nature Review Disease Primers. November 2018

  16. Slide 16: MSC-NTF Progressive MS Disease Targets: Inflammation and Neurodegeneration

    ‫בס"ד‬ MSC-NTF Progressive MS Disease Targets: Inflammation and Neurodegeneration Reduced Inflammation Neuroprotection Images Courtesy Dr J Cohen

  17. Slide 17: Intracerebroventricular NTF cells improves motor function and survival in rodent MS model

    ‫בס"ד‬ Intracerebroventricular NTF cells improves motor function and survival in rodent MS model (EAE) Intracerebroventricular injection of 2.5X105 cells Barhum et al 2009 J. Mol. Neur.

  18. Slide 18: Progressive MS Phase 2 Study

    ‫בס"ד‬ Progressive MS Phase 2 Study • IND accepted by FDA December 15, 2018 • Cell manufacturing Dana Farber Cancer Institute • Study start up activities underway • Protocol, site details and participant enrollment timelines will be disclosed in the first quarter 18

  19. Slide 19: Financial Highlights

    ‫בס"ד‬ Financial Highlights $US in Thousands (except for Shares, Warrants and Options data) September 30, 2018 Cash and cash equivalents 697 Short-term deposit 10,194 Non-Dilutive Grants 8,000 Total Liquidity 18,891 Cap Structure Debt - Shares Outstanding (including outstanding Warrants and Options)

  20. Slide 20: IP Portfolio

    ‫בס"ד‬ IP Portfolio Allowed Granted Patent Name/ Int. App. No. Pending Jurisdictions Expiry Date Jurisdictions Jurisdictions ISOLATED CELLS AND POPULATIONS COMPRISING SAME FOR THE TREATMENT OF CNS US Europe, US 2030 DISEASES/PCT/IL2006/000699 MESENCHYMAL STEM CELLS FOR THE TREATMENT OF Hong Kong US,

  21. Slide 21: BrainStorm Management Team

    ‫בס"ד‬ BrainStorm Management Team Chaim Lebovits Yael Gothelf PhD. President and CEO VP, Scientific and Regulatory Affairs Ralph Kern, MD, MHSc. Uri Yablonka COO and CMO EVP, Chief Business Officer Eyal Rubin Yossef Levy PhD. EVP, CFO VP, Cell Production Mary Kay Turner Revital Aricha PhD. VP, Patie

  22. Slide 22: Thank You

    ‫בס"ד‬ BrainStorm Cell Therapeutics NASDAQ: BCLI Thank You

BrainStorm Cell Therapeutics — Investor Presentation (February 2019) on 6ix